NASDAQ:CBAY CymaBay Therapeutics (CBAY) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$32.48▼$32.4850-Day Range$32.18▼$32.4852-Week Range$7.26▼$32.50Volume73 shsAverage Volume4.11 million shsMarket Capitalization$3.73 billionP/E RatioN/ADividend YieldN/APrice Target$31.44 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipSustainabilityTrendsStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipSustainabilityTrends Get CymaBay Therapeutics alerts: Email Address CymaBay Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside3.2% Downside$31.44 Price TargetShort InterestN/ADividend StrengthN/ASustainability-0.88Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.38) to ($1.37) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.40 out of 5 starsMedical Sector872nd out of 910 stocksPharmaceutical Preparations Industry407th out of 426 stocks 1.0 Analyst's Opinion Consensus RatingCymaBay Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 11 hold ratings, and no sell ratings.Amount of Analyst CoverageCymaBay Therapeutics has received no research coverage in the past 90 days.Read more about CymaBay Therapeutics' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for CBAY. Previous Next 0.0 Dividend Strength Dividend YieldCymaBay Therapeutics does not currently pay a dividend.Dividend GrowthCymaBay Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCymaBay Therapeutics has received a 74.24% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for CymaBay Therapeutics is -0.88. Previous Next N/A News and Social Media Coverage Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CymaBay Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.00% of the stock of CymaBay Therapeutics is held by insiders.Percentage Held by Institutions95.03% of the stock of CymaBay Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about CymaBay Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for CymaBay Therapeutics are expected to grow in the coming year, from ($1.38) to ($1.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CymaBay Therapeutics is -33.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CymaBay Therapeutics is -33.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCymaBay Therapeutics has a P/B Ratio of 12.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About CymaBay Therapeutics Stock (NASDAQ:CBAY)CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.Read More Ad Porter & CompanyWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. CBAY Stock News HeadlinesJuly 29, 2024 | stocknews.com3 Biotech Stocks With Revolutionary Pipelines to Buy TodayMarch 22, 2024 | za.investing.comGilead reduces 2024 earnings guidance after completing CymaBay takeoverSeptember 7, 2024 | Porter & Company (Ad)Trump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…March 22, 2024 | markets.businessinsider.comGilead Sciences Completes Acquisition Of CymaBay TherapeuticsMarch 22, 2024 | businesswire.comGilead Sciences Announces Completion of Acquisition of CymaBayMarch 16, 2024 | finance.yahoo.comCBAY Jul 2024 34.000 callMarch 16, 2024 | finance.yahoo.comCBAY Apr 2024 31.000 putMarch 16, 2024 | finance.yahoo.comCBAY Oct 2024 33.000 callSeptember 7, 2024 | Porter & Company (Ad)Trump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…March 16, 2024 | finance.yahoo.comCBAY Oct 2024 29.000 putMarch 11, 2024 | finance.yahoo.comInvesting in CymaBay Therapeutics (NASDAQ:CBAY) three years ago would have delivered you a 540% gainMarch 4, 2024 | globenewswire.comCymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary CholangitisFebruary 29, 2024 | markets.businessinsider.comMaintaining Hold on CymaBay Amid Gilead Acquisition Deal ClosureFebruary 29, 2024 | markets.businessinsider.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of CymaBay Therapeutics, Inc. (CBAY)February 28, 2024 | marketwatch.comCymaBay Therapeutics 4Q Loss/Shr 35c >CBAYFebruary 28, 2024 | globenewswire.comCymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate UpdateFebruary 24, 2024 | msn.comCymaBay Therapeutics (CBAY) Price Target Increased by 12.84% to 31.37February 21, 2024 | finance.yahoo.comThe New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary CholangitisSee More Headlines Receive CBAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CymaBay Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today9/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CBAY CUSIPN/A CIK1042074 Webwww.cymabay.com Phone(510) 293-8800Fax510-293-9090Employees101Year FoundedN/APrice Target and Rating Average Stock Price Target$31.44 High Stock Price Target$32.50 Low Stock Price Target$24.00 Potential Upside/Downside-3.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($0.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-105,370,000.00 Net MarginsN/A Pretax Margin-339.11% Return on Equity-50.72% Return on Assets-31.04% Debt Debt-to-Equity RatioN/A Current Ratio10.96 Quick Ratio10.96 Sales & Book Value Annual Sales$31.07 million Price / Sales119.92 Cash FlowN/A Price / Cash FlowN/A Book Value$2.58 per share Price / Book12.59Miscellaneous Outstanding Shares114,724,000Free Float106,693,000Market Cap$3.73 billion OptionableOptionable Beta0.32 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Sujal A. Shah (Age 51)President, CEO & Director Comp: $1.04MDr. Charles A. McWherter Ph.D. (Age 69)President of Research & Development and Chief Scientific Officer Comp: $700.65kMr. Paul T. Quinlan (Age 61)General Counsel, Chief Compliance Officer & Corporate Secretary Comp: $629.72kMr. Harish Shantharam C.F.A. (Age 42)CFO, Principal Accounting & Financial Officer Mr. Ken BoehmSenior Vice President of Human ResourcesMr. Patrick J. O'Mara (Age 63)Senior Vice President of Business Development Dr. Robert L. Martin (Age 62)Senior Vice President of Manufacturing & Nonclinical Development Ms. Klara A. Dickinson-Eason (Age 56)Chief Regulatory & Quality Assurance Officer Comp: $441.84kMs. Becki Filice (Age 63)Senior Vice President of Portfolio & Product Leadership Mr. Ben KozubHead of CommercialMore ExecutivesKey CompetitorsMirum PharmaceuticalsNASDAQ:MIRMPandion TherapeuticsNASDAQ:PANDAvid BioservicesNASDAQ:CDMOUrovant SciencesNASDAQ:UROVG1 TherapeuticsNASDAQ:GTHXView All CompetitorsInsidersJanet DorlingSold 6,000 sharesTotal: $191,820.00 ($31.97/share)Charles McwherterSold 18,403 sharesTotal: $435,599.01 ($23.67/share)Daniel MenoldSold 10,000 sharesTotal: $235,800.00 ($23.58/share)Paul T. QuinlanSold 5,000 sharesTotal: $117,900.00 ($23.58/share)Janet DorlingSold 6,000 sharesTotal: $143,160.00 ($23.86/share)View All Insider Transactions CBAY Stock Analysis - Frequently Asked Questions How were CymaBay Therapeutics' earnings last quarter? CymaBay Therapeutics, Inc. (NASDAQ:CBAY) released its earnings results on Wednesday, February, 28th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by $0.04. The biopharmaceutical company earned $0.06 million during the quarter, compared to analysts' expectations of $0.42 million. What other stocks do shareholders of CymaBay Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that CymaBay Therapeutics investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Advanced Micro Devices (AMD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA) and Novavax (NVAX). This page (NASDAQ:CBAY) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CymaBay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CymaBay Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
